Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: A population-based natural experiment

Circulation

Volumn 115, Issue 16, 2007, Pages 2128-2135

  Schneeweiss, Sebastian ^a,b   Patrick, Amanda R ^a   Maclure, Malcolm ^b,c   Dormuth, Colin R ^a   Glynn, Robert J ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF VICTORIA   (Canada)

Author keywords

Drugs; Economics, pharmaceutical; Health care costs; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE HEART INFARCTION; AGED; ARTICLE; CANADA; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG COST; DRUG WITHDRAWAL; FEMALE; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; LOGISTIC REGRESSION ANALYSIS; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BRITISH COLUMBIA; COHORT STUDIES; COST SHARING; DEDUCTIBLES AND COINSURANCE; DRUG COSTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSURANCE COVERAGE; INSURANCE, PHARMACEUTICAL SERVICES; MALE; MYOCARDIAL INFARCTION; NATIONAL HEALTH PROGRAMS; PATIENT COMPLIANCE;

EID: 34247524091     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.106.665992     Document Type: Article

References (50)

1. Heffler S, Smith S, Keehan S, Clemens MK, Zezza M, Truffer C. Health spending projections through 2013. Health Aff (Millwood). 2004; suppl Web exclusives:W4-79-93.
2. Strunk BC, Ginsburg PB: Tracking health care costs: trends turn downward in 2003. Health Aff (Millwood). 2004; suppl Web exclusives: W4-354-362.
3. Hoadley J, Hargrave E, Cubanski J, Neuman T. An in-depth examination of formularies and other features of Medicare drug plans: Menlo Park, Calif; Henry J Kaiser Family Foundation; April 2006. Publication No. 7489.
4. Schneeweiss S, Walker AM, Glynn RJ, Maclure M, Dormuth C, Soumerai SB. Outcomes of reference pricing for angiotensin-converting enzyme inhibitors. N Engl J Med. 2002;346:822-829.
5. Grootendorst PV, Dolovich LR, O'Brien BJ, Holbrook AM, Levy AR. Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs. Can Med Assoc J. 2001;165:1011-19.
6. Schneeweiss S, Soumerai SB, Maclure M, Dormuth C, Walker AM, Glynn RJ. Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers. Clin Pharm Ther. 2003;74:388-400.
7. Marshall JK, Grootendorst PV, O'Brien BJ, Dolovich LR, Holbrook AM, Levy AR. Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia. Can Med Assoc J. 2002;166:1655-1662.
8. Schneeweiss S, Maclure M, Carleton BC, Glynn RJ, Avorn J. Clinical and economic consequences of a formulary restriction of nebulized respiratory drugs in adults: direct comparison of randomized and observational evaluations. BMJ. 2004;328:560-564.
9. Schneeweiss S, Dormuth C, Grootendorst P, Soumerai S, Maclure M. Net health plan savings from reference drug pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents. Med Care. 2004;42:653-660.
10. Schöffski O: Consequences of implementing a drug budget for office based physicians in Germany. Pharmacoeconomics. 1996;10(suppl 2):37-47.
11. Soumerai SB, Ross-Degnan D, Avorn J, McLaughlin T, Choodnovskiy I. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N Engl J Med. 1991;325:1072-1077.
12. Motheral B, Fairman KA. Effect of a three-tier prescription copay on pharmaceutical and other medical utilization. Med Care. 2001;39:1293-1304.
13. Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med. 2003;349:2224-2232.
14. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica W, Arnold JMO, Wun CC, Davis BR, Braunwald E; for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
15. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
16. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
17. Lewis SJ, Moye LA, Sacks FM, Johnstone DE, Timmis G, Mitchell J, Limacher M, Kell S, Glasser SP, Grant J, Davis BR, Pfeffer MA, Braunwald E. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range: results of the Cholesterol And Recurrent Events (CARE) trial. Ann Intern Med. 1998;129:681-689.
18. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG; PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623-1630.
19. Grundy SM, Balady GJ, Criqui MH, Fletcher G, Greenland P, Hiratzka LF, Houston-Miller N, Kris-Etherton P, Krumholz HM, LaRosa J, Ockene IS, Pearson TA, Reed J, Smith SC Jr, Washington R. When to start cholesterol-lowering therapy in patients with coronary heart disease. Circulation. 1997;95:1683-1685.
20. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Adult Treatment Panel II. JAMA. 1993;269:3015-3023.
21. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
22. Jackevicius CA, Anderson GM, Leiter L, Tu JV. Use of the statins in patients after acute myocardial infarction. Arch Intern Med. 2001;161:183-188.
23. Ayanian JZ, Landrum MB, McNeil BJ. Use of cholesterol-lowering therapy by elderly adults after myocardial infarction. Arch Intern Med. 2002;162:1013-1019.
24. Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, LeLorier J. Persistence of use of lipid-lowering medications: a cross-national study. JAMA. 1998;279:1458-1462.
25. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288:455-461.
26. Tu JV, Donovan LR, Austin PC, Ko DT, Newman AM, Wang J, Fang J. Quality of Cardiac Care in Ontario-Phase I. Toronto, Canada: Institute for Clinical Evaluative Sciences; 2005. Report 2.
27. Marmot M. The influence of income on health: views of an epidemiologist. Health Aff. 2002;21:31-46.
28. Deaton A. Policy implications of the gradient of health and wealth. Health Aff. 2002;22:13-30.
29. British Columbia Ministry of Health. PharmaNet. Available at: http://www.healthservices.gov.bc.ca/ pharme/pharmanet/netindex.html. Accessed March 21, 2007.
30. Williams JI, Young W. Inventory of Studies on the Accuracy of Canadian Health Administrative Databases. Toronto, Canada: Institute for Clinical Evaluative Sciences; December 1996. Technical report.
31. Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH. The accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value based on review of hospital records. Am Heart J. 2004;148:99-104.
32. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50:105-116.
33. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15:565-574.
34. The Coronary Drug Project: influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project. N Engl J Med. 1980;303:1038-1041.
35. Dormuth CR, Glynn RJ, Neumann P, Maclure M, Brookhart AM, Schneeweiss S. Impact of two sequential drug cost-sharing policies on the use of inhaled medications in older patients with chronic obstructive pulmonary disease or asthma. Clin Ther. 2006;28:964-978.
36. Warburton RN. Takeup of income-tested health-care premium subsidies: evidence and remedies for British Columbia. Can Tax J. 2005;53:1-28.
37. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
38. Warburton RN. Takeup of income-tested health-care premium subsidies: evidence and remedies for British Columbia. Can Tax J. 2005;53:1-28.
39. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27:299-309.
40. Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13-22.
41. Fitzmaurice GM, Laird NM, Ware JH. Applied Longitudinal Analysis. Hoboken, NJ: Wiley; 2004.
42. BC Stats. Available at: http://www.bcstats.gov.bc.ca/. Accessed January 20, 2006.
43. Schlenk EA, Dunbar-Jacob J, Engberg S. Medication non-adherence among older adults: a review of strategies and interventions for improvement. J Gerontol Nurs. 2004;30:33-43.
44. Choudhry NK, Avorn J, Antman E, Schneeweiss S, Shrank WH. Should post-MI patients receive secondary prevention medications for free? An empirical policy analysis. Health Aff. 2007;26:186-194.
45. Tamblyn R, Laprise R, Hanley JA, Abrahamowicz M, Scott S, Mayo N, Hurley J, Grad R, Latimer E, Perreault R, Mcleod P, Huang A, Larochelle P, Mallet L. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA. 2001;285:421-429.
46. Roblin DW, Platt R, Goodman MJ, Hsu J, Nelson WW, Smith DH, Andrade SE, Soumerai SB. Effect of increased cost-sharing on oral hypoglycemic use in five managed care organizations: how much is too much? Med Care. 2005;43:951-959.
47. Soumerai SB, Ross-Degnan D, Fortess EE, Abelson J. A critical analysis of studies of state drug reimbursement policies: research in need of discipline. Milbank Q. 1993;71:217-252.
48. Schneeweiss S, Maclure M, Soumerai SB, Walker AM, Glynn RJ. Quasi-experimental longitudinal designs to evaluate drug benefit policy changes with low policy compliance. J Clin Epidemiol. 2002;55:833-841.
49. Schneeweiss S, Maclure M, Dormuth C, Glynn RJ, Canning C, Avorn J. A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequences. Clin Pharm Ther. 2006;79:379-388.
50. CMS: final rules for the MMA. Fed Regist. 2005;70:4460.